Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses

被引:8
|
作者
Campione, Elena [1 ]
Rivieccio, Antonia [1 ]
Shumak, Ruslana Gaeta [1 ]
Costanza, Gaetana [2 ]
Cosio, Terenzio [1 ,2 ]
Lambiase, Sara [1 ]
Garofalo, Virginia [1 ]
Artosi, Fabio [1 ]
Lozzi, Flavia [1 ]
Freni, Claudia [3 ]
Romeo, Alice [3 ]
Dika, Emi [4 ]
Falconi, Mattia [3 ]
Bianchi, Luca [1 ]
机构
[1] Univ Roma Tor Vergata, Dept Syst Med, Dermatol Unit, I-00133 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy
[3] Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy
[4] Univ Bologna, Oncol Dermatol Unit, IRCCS Azienda Osped Univ Bologna, DIMEC, I-40126 Bologna, Italy
关键词
tirbanibulin; actinic keratosis; field of cancerization; SQUAMOUS-CELL CARCINOMA; PIROXICAM; 0.8-PERCENT; IMMUNE-RESPONSE; SKIN; GUIDELINES; MANAGEMENT; INSIGHTS; CARE;
D O I
10.3390/ph16121686
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Actinic keratosis is a common precancerous skin lesion that can progress into invasive squamous cell carcinomas. Many topical treatments for actinic keratoses often have poor tolerability and prolonged duration. Tirbanibulin is a novel synthetic drug with potent antitumor and antiproliferative activities. Methods: We conducted a single-center, prospective and observational study using tirbanibulin ointment on a 25 cm2 area for 5 consecutive days on 30 participants with AKs on the face or scalp. They were followed for at least 57 days to assess the safety profile and efficacy of the drug as well as treatment satisfaction. We evaluated six signs of local skin reaction (LSR): erythema, scaling, crusting, swelling, blisters/pustules, and erosions/ulcerations, grading the severity as mild, moderate, or severe. The effectiveness was evaluated both clinically and dermoscopically. The treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Results: On day 57, 70% of the patients showed a complete clinical and dermoscopic response. The highest scores obtained from the TSQM 1.4 were more evident in the convenience and side effects domains. Most LSRs, including erythema (83.3%), scaling (30%), and swelling (3.3%), occurred on day 8 but resolved spontaneously. Conclusion: Tirbanibulin is a viable therapeutic option with a short regimen treatment and good tolerability, which favors therapy adherence.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Efficacy and safety of a thermal fractional skin rejuvenation system (Tixel) for the treatment of facial and/or scalp actinic keratoses
    Oren-Shabtai, Meital
    Sloutsky, Nadezhda
    Lapidoth, Moshe
    Mimouni, Daniel
    Chorny, Ilia
    Snast, Igor
    Leshem, Yael Anne
    Friedland, Rivka
    Hodak, Emmilia
    Klein, Ifat
    Agmon, Yael
    Levi, Assi
    LASERS IN MEDICAL SCIENCE, 2022, 37 (07) : 2899 - 2905
  • [22] Safety and Tolerability of Tirbanibulin Ointment 1% over a Large Field (up to 100 cm2) in Actinic Keratosis: A Phase 3 Study
    Bhatia, Neal
    Blauvelt, Andrew
    Lain, Edward
    Jarell, Abel
    DuBois, Janet
    Tomondy, Paul
    Falques, Meritxell
    Kiyasova, Vera
    Padulles, Laura
    Otero, Raquel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB221 - AB221
  • [23] The efficacy and safety of topical 5% 5-fluorouracil in renal transplant recipients for the treatment of actinic keratoses
    Ingham, Annabel I.
    Weightman, Warren
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 (03) : 204 - 208
  • [24] The safety and efficacy of daylight photodynamic therapy in the treatment of actinic keratoses: a systematic review and meta-analysis
    Zhao, Weijia
    Guan, Meng
    Nong, Xiang
    Li, Qian
    Chen, Zonghan
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2019, 58 (02) : 159 - 166
  • [25] Efficacy and safety of a thermal fractional skin rejuvenation system (Tixel) for the treatment of facial and/or scalp actinic keratoses
    Meital Oren-Shabtai
    Nadezhda Sloutsky
    Moshe Lapidoth
    Daniel Mimouni
    Ilia Chorny
    Igor Snast
    Yael Anne Leshem
    Rivka Friedland
    Emmilia Hodak
    Ifat Klein
    Yael Agmon
    Assi Levi
    Lasers in Medical Science, 2022, 37 : 2899 - 2905
  • [26] Topical Treatment of Actinic Keratoses with Piroxicam 1% Gel A Preliminary Open-Label Study Utilizing a New Clinical Score
    Campione, Elena
    Diluvio, Laura
    Paterno, Evelin Jasmine
    Chimenti, Sergio
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2010, 11 (01) : 45 - 50
  • [27] Topical Treatment of Actinic Keratoses with Piroxicam 1% GelA Preliminary Open-Label Study Utilizing a New Clinical Score
    Elena Campione
    Laura Diluvio
    Evelin Jasmine Paternò
    Sergio Chimenti
    American Journal of Clinical Dermatology, 2010, 11 : 45 - 50
  • [28] Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm2: A Phase 1 Maximal-Use Trial in Patients with Actinic Keratosis
    Dubois, Janet
    Jones, Terry M.
    Lee, Mark S.
    Falques, Meritxell
    Kiyasova, Vera
    Jimenez, Gemma
    Otero, Raquel
    Jansat, Josep-M.
    Aubets, Jordi
    Forconi, Rion James
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (02): : 208 - 218
  • [29] Efficacy and Safety of Photodynamic Therapy for the Treatment of Actinic Keratoses: A Meta-Analysis Update of Randomized Controlled Trials
    Hu, Chengjun
    Luo, Xiangyue
    Jiang, Chufeng
    Lei, Shaorong
    Sun, Yuming
    DERMATOLOGIC SURGERY, 2023, 49 (06) : 544 - 551
  • [30] Safety and efficacy of ingenol mebutate gel 0.015%, for treatment of actinic keratoses on the face in solid organ transplant recipients
    Crow, Lauren D.
    Yuan, Joyce T.
    Aroyan, Christine S.
    Twigg, Amanda R.
    Singer, Jonathan P.
    Roll, Garrett R.
    Lazar, Ann A.
    Arron, Sarah T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB270 - AB270